CD133 (Prominin-1) Monoclonal Antibody (EMK08), FITC, eBioscience™, Invitrogen™

Description

• The EMK08 monoclonal antibody reacts with human CD133 (Prominin-1), a 120 kDa member of the pentaspan family of proteins, which also includes Prominin-2
• Their expression is found within plasma membrane protrusions such as epithelial microvilli
• CD133 can exist in a number of alternatively spliced isoforms, and the protein has several N-linked glycosylation sites; the occurrence of both may be tissue-dependent
• Human CD133 was first identified as an epitope expressed on CD34+ hematopoietic progenitors
• Although the ligand and function of CD133 remain unknown, it has since proven to be very useful as a marker for both stem cells and cancer stem cells
• In addition to its expression on hematopoietic precursors, CD133 has been used to identify tumorigenic colon cancer stem cells, brain cancer stem cells, prostate cancer stem cells, in addition to others
• The binding of the EMK08 antibody does not block the binding of another anti-human CD133 antibody, TMP4 (cat
• 12-1338) indicating that they recognize distinct epitopes
• This EMK08 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.06 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Filtration: 0.2 μm post-manufacturing filtered
• The CD133 (AC133) antigen is a 97 kDa glycoprotein, with 5 transmembrane domains, that shows up as a 120 kDa band on protein gels due to glycosylation
• CD133 is a cell surface marker expressed by immature hematopoietic stem cells but not mature blood cells
• In addition to hematopoietic stem and progenitor cells, CD133 has been found to be a marker for other stem and progenitor cells including neural and embryonic stem cells
• CD133 has been shown to be expressed in cancers, including some leukemias and brain tumors, that may be derived from stem cells
• Low level expression could also be detected in the kidney, pancreas, placenta, and fetal liver
• Mutations in this gene have been shown to result in retinitis pigmentosa and Stargardt disease
• Expression of the CD133 gene is also associated with several types of cancer
• CD133 is expressed from at least five alternative promoters that are expressed in a tissue-dependent manner, and multiple transcript variants encoding different isoforms have been found.